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Introduction
Total laryngectomy(TL) isstillan indispensabletreatmentoption
for advanced larynx and hypopharynx cancer, for recurrent
disease, and a dysfunctional larynx after prior (chemo) radio-
therapy (C)RT. Total laryngectomy results in signiﬁcant anato-
mical changes. The alimentary and respiratory tracts are
separated and a deﬁnitive tracheostomy is created at the base
of the neck. The main disadvantage of TL is the loss of upper
airway and larynx functions. This leads to pulmonary problems,
such as excessive coughing and mucus production, and loss of
normal speech.1,2
To prevent or diminish pulmonary problems, continuous
use of a heat and moisture exchanger (HME) has shown to be
highlybeneﬁcial.3,4Moreover,mostautomatic speaking valves
(ASVs) presently are combined with an HME, so that during
hands-free tracheoesophageal speech, airway protection and
rehabilitation are also taken care of.5–7 Laryngectomized
patients have several options to keep these devices in place






Abstract Introduction To prevent or diminish pulmonary problems in laryngectomized
patients, continuous use of a heat and moisture exchanger (HME) is recommended.
Therefore, automatic speaking valves are also often combined with an HME to enable
hands-free speech. In order to keep these devices in place, most commonly, peristomal
patches are used.
Objective This prospective clinical 2  2 crossover study aims at assessing the added
value of a new patch for HME application, the Provox StabiliBase OptiDerm (SBO). The
device combines the stable and conical base of the Provox StabiliBase with the skin-
friendlier hydrocolloid Provox OptiDerm (OD) patch.
Methods Thirty-two laryngectomized patients were included in this multicenter
study. Participants were asked to compare SBO to OD, and to the patch they normally
use. The primary outcome measure was patient preference.
Results Overall, 60% of the participants had preference for their normally used patch,
23% preferred the SBO and 17% indicated no preference. When comparing the SBO to
the OD, 43% preferred the SBO, 40% the OD and 17% had no preference.
Conclusion Most patients preferred their normally used patch and SBO was favored
by a subgroup. Provox StabiliBase OptiDerm seems to be a valuable addition to the
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useddevice is aperistomalpatch,which creates anairtight seal
at the level of the tracheostoma and provides a placeholder for
the HME and/or ASV.8
Currently, there is awide variety of patches available to suit
patients’ personal needs, which is important to optimize
compliance.8–10 Recently, the Provox StabiliBase (SB) was eval-
uated in amulticenter study. This patch provides amore stable
and more anatomically shaped conical base compared with
other patches. The study showed that the majority of patients
preferred this new patch to their usual comparator, and its
device life appeared to be signiﬁcantly longer. Also, patients
with a deep stoma reported the patch to bemore comfortable.9
After its introduction, feedback fromclinicians andpatients
revealed that some patients experienced skin irritation with
the standard adhesive material of the SB. It was felt that these
patients would beneﬁt from a patch with the same stable and
conical base as the SB, but with themore skin-friendly hydro-
colloid adhesive already used in the Provox OptiDerm (OD).
Therefore, the Provox StabiliBase OptiDerm (SBO) was devel-
oped. To test whether this stable conical hydrocolloid SBO
patch is a valuable addition to the variety of peristomal
adhesive options needed to suit more laryngectomized
patients, this new patch was assessed in a 2  2 crossover
prospective multicenter clinical trial.
Methods
This study was performed at two tertiary care cancer centers.
Thirty-two laryngectomized patients were entered in the
study, 16 from each center. Inclusion criteria were: 18 years
or older, use of an HME, use of a voice prosthesis, minimum of
3 months after TL and/or postoperative (C)RT. Exclusion
criteria were: patient is unable to use the SBO (due to anato-
mical irregularities that may interfere with the stable base of
the patch), medical problems prohibiting the use of HME or
patch, active recurrent or metastatic disease, patient is unable
to understand the patient information and/or unable to give
informed consent. Skin irritation, which varies between 9 and
40% among patients,4,10–12 was not a selection criterion. This
provides us with two advantages, namely additional data on
the extent of the skin irritation problem in this patient cohort,
and prevention of selection bias. Moreover, it is likely that, if
given more options and provided that there was no skin
irritation, patients would primarily make their choice on the
basis of the duration of the seal. In other words, by using an
unselected patient cohort, we can get a better insight of the
extent of the irritation problem and of the place of this new
patch among the presently available options. The study was
performed according to the protocol approved by the institu-
tional review boards and took place between February and
April of 2014. Signed informed consent was obtained from all
patients. Patient characteristics are shown in ►Table 1.
The SBO is manufactured by Atos Medical AB (Hörby,
Sweden). The patch is shown in►Fig. 1. It is a single-use patch
intended for laryngectomizedpatients. It is attached to theskin
aroundthetracheostomatoprovideaconnection forHMEsand
speaking valves. The SBO consists of a stable base, similar to
that of the SB, but with a hydrocolloid adhesive.9 The patch is
suitable for sensitive and/or breached skin and its baseplate is
designed to also accommodate deep tracheostomas.
The SBO was compared with the OD in a feasibility study
with a 2  2 crossover design. After inclusion, the patients





Age at TL Mean 55.7 years (SD 9.4)
Age at entry Mean 64.0 years (48–82)




þ Reconstruction 3 9
















Provox 2 4 13
Provox Vega 18 56









þ ASV use 9 28
Abbreviations: ASV, Automatic SpeakingValve; (C)RT, (chemo)radiotherapy;
HME, Heat and Moisture Exchanger; TL, Total Laryngectomy; SD, standard
deviation.
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consecutively used 5 OD and 5 SBO patches in the order
assigned by randomization. The primary outcome measure
was overall patient preference, based on the various aspects of
the patch addressed in the study-speciﬁc questionnaires (see
below). The secondary outcome parameters were: device life,
patient satisfaction (skin irritation, comfort, voice/speech),
ease of application, and quality of life. Study-speciﬁc struc-
tured questionnaires were completed at baseline, after the use
of theﬁrst5patchesandafter theuseof thefollowing5patches.
Questionnaires addressed skin irritation, ease of application,
ease of removal, cleanliness,mucus collection,ﬁt, comfort, use
of other devices in combination with patch, appearance, voice
quality, air leakage, adherence and cleaning tracheostomy/
voice prosthesis. Answers were reported on a four-level Likert
scale. Patients rated satisfaction regarding device life and voice
quality using a 10-cm Numeric Rating Scale (NRS) (0 ¼ worst
and10 ¼ best).Qualityof lifewasassessedusing theEuroQOL-
5 Dimension-5 Level questionnaire (Eq. 5D5L).13 The Eq. 5D5L
is a validated instrument using scores in ﬁve health care
dimensions (mobility, self-care, daily activities, pain/discom-
fort and anxiety/depression) and a 100-mm visual analogue
scale (VAS). During the study period, patients kept a diary to
record thedevice life ofeachpatchand thenumberofhoursper
day of HME use. At the end of the study patients were asked to
complete a comparative questionnaire. Patients had to com-
pare the SBO with the OD and also with their normally used
patch if different from the OD.
The primary outcome of this study was patient preference.
The goal was that 40% of the participants preferred the SBO to
the OD, 5% considered the SBO to be worse, whereas the
remainder considered both patches to be equally good (45%)
or bad (10%). Based on earlier studies andgiven the assumption
that in the absence of irritation, the duration of the seal is the
deciding factor, this was a feasible goal to be expected and
clinically relevant.9,10,12 A sample size of 30 pairs will have 82%
ofpower todetect adifference inproportionsof0.350,whilethe
proportion of discordant pairs is expected to be 0.450, using a
sign testofequalityof pairedproportionswith a 0.05 two-sided
level of signiﬁcance. As this was a short study and no risks have
beenassociatedwithparticipation in thestudy, thedropout rate
was expected to be < 5%. Statistical analyses were conducted
using the IBMStatisticalPackagefor theSocial Sicencessoftware
(IBM Corp., Armonk, NY, US), version 22.0. Frequencies were
explored using the Kolmogorov-Smirnov test. Parametrically
distributed data are shown as mean  standard deviation and
analyzed using the paired t-test. Non-parametrical data are
presented as median (inter quartile range) and were analyzed
using theWilcoxon signed-rank test. The Likert Scales rendered
ordinal data fromthree related samples. This datawas analyzed
using the Friedman test. If the groups differed signiﬁcantly, a
Wilcoxon signed-rank testwasused todeterminewhichgroups
were different. A p-value < 0.05 was considered signiﬁcant.
Results
The characteristics of the 32 patients enrolled in the study
are shown in►Table 1. One patient withdrew from the study
in the ﬁrst week because of recurrent disease and was
excluded from further analysis. Twenty-seven males and
four females remained. Four patients did not use all of the
study patches. Reasons were: skin irritation after using the
SBO, poor adherence of the SBO to the skin, poor adherence of
the OD to the skin and painful skin after using the OD. An
overview of completed questionnaires is shown in ►Table 2.
Fig. 1 StabiliBase OptiDerm (SBO); (A) a technical drawing of the SBO
without liner (frontal view) showing the stable and conical base; (B)
attached to a patient with the heat and moisture exchanger in situ.





Comparative ‘Normally used patch’ – SBO 25/
Comparative OD – SBO 30
Abbreviations: OD, OptiDerm; SBO, StabiliBase OptiDerm.
Notes: One patient dropped out right after baseline data collection.
These data were removed from the analysis.
One patient did not complete the OD questionnaire (poor adherence).
 One patient did not complete the SBO questionnaire and the
comparative questionnaires (poor adherence).
 For the ﬁve patients who were already using OD at baseline,
the OD-SBO comparative questionnaire was used as normally used
patch-SBO comparative questionnaire.
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When patients compared the OD with the SBO, 12 of 30
patients (40.0%) preferred the OD. Thirteen patients preferred
theSBO(43.3%) and5patients (16.7%) expressednopreference.
In comparison with their normally used patch, 18 patients
(60.0%) indicated a preference for the normally used patch,
7 patients (23.3%) for the SBO and 5 patients (16.7%) indicated
no preference. Of the 5 patients who were using the OD at
baseline (preference for OD 3, for SBO 1, no preference 1), the
answers to the comparative OD-SBO questionnaire were used
as ‘normally used patch-SBO-data’ in these analyses (►Fig. 2).
Device life assessment was based on the data provided by
the patients, who reported on at least 3 out of 5 OD/SBO
patches. For the OD, the median device life was 18.5 hours
(n ¼ 26; range 0.5–109.9) and for the SBO this was 19.6 hours
(n ¼ 27; range 0.5–163.0) (p ¼ 0.290). When data were split
for patches used to apply an ASV or a HME, no signiﬁcant
differences were found between device life of the SBO and OD.
Therewasan increase indevice life in15outof26patientswith
the SBO comparedwith theOD,with amean factor of 1.44. In 2
patients, therewasnodifference, and in9 patients, therewas a
decrease of the device lifewith the SBO comparedwith theOD
with a mean factor of 0.76. The overall mean factor was 1.17.
Themedian self-reporteddevice life in the15patientswhohad
an increased device life with the SBO, was 14.47 hours (range
1.9–109.9) with the OD and 19.60 hours (range 2.35–163.01)
with the SBO.
Analysis of ﬁt, comfort, appearance, speech, air leakage
and adherence, measured at baseline, after using 5 OD
patches and after using 5 SBO patches, showed a statistically
signiﬁcantly better outcome for the normally used patch
compared with the SBO and the OD. No signiﬁcant differ-
ences regarding these variables were found between the SBO
and OD.
With respect to skin irritation, no signiﬁcant difference
was found between the normally used patch, OD and SBO.
When asked to compare these two patches, 17% experienced
less skin irritation with the OD, 23% experienced less skin
irritation with the SBO and 60% experienced no difference
(n ¼ 30). Compared with the normally used patch (n ¼ 25),
12% experienced less skin irritationwith that patch, 32%with
the SBO and 56% experienced no difference.
Participants indicated signiﬁcantly less discomfort with
their normally used patch compared with the SBO
(p ¼ 0.001, n ¼ 30). When asked to compare the normally
used patch with the SBO, 52% found that patch more com-
fortable to wear, 24% found the SBO more comfortable and
24% found no difference.When asked to compare the OD and
SBO, 33% had less discomfort with the SBO, 40% with the OD
and 27% indicated no difference.
Overall voice and speech was measured using a NRS.
There was no statistically signiﬁcant difference between
the normally used patch and the SBO. Only the OD received
a statistically signiﬁcantly lower score compared with the
normally used patch (p ¼ 0.004, n ¼ 30), and comparedwith
the SBO (p ¼ 0.007, n ¼ 30). Furthermore, no signiﬁcant
differences in applying the patch and in the quality of life
(according to Eq. 5D5L) between the normally used patch, OD
and SBO were found.
Finally, regarding future use, 15 out of 28 patients (53.6%)
reported that they would keep their normally used patch in
the future. Of the 13 remaining patients answering this
question, 6 (21.4%) will use the OD, 5 (17.9%) the SBO and
2 (7.1%) a combination of the normally used patch with SBO.
Data of two patients weremissing. Those seven patients who
will use the SBO or a combination of the normally used patch
and SBO in the future consist of two former regular patch
users (29%), four SBusers (57%) and one tracheostomybutton
user (14%).
During this study, six adverse device effects were regis-
tered. There were complaints about skin irritation, painful
removal of the patch and poor adherence. All reports were
expected effects of using a tracheostomy patch.
Fig. 2 To illustrate the added value of more patch choices, on the left, the preference at the end of the study for either of the 2 hydrocolloid
patches (SBO ¼ StabiliBase OptiDerm, n ¼ 13; OD ¼ OptiDerm, n ¼ 12; No pref ¼ No preference for either of the two, n ¼ 5); on the right, the
preference in comparison with (icw) the normally used patch (NU ¼ normally used patch, n ¼ 18; SBO, n ¼ 7; No pref. n ¼ 5).
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Discussion
This prospective clinical trial on the evaluation of the SBO, a
new patch with stable conical base and hydrocolloid adhe-
sive for peristomal attachment of postlaryngectomy pul-
monary and voice rehabilitation, shows that this patch is a
valuable addition to the variety of options needed to suit
more laryngectomized patients.
With a quarter of the patients choosing the SBO, or a
combination of the normally used patch with the SBO, it is
clear that the SBO is suitable for a subgroup of patients. This
subgroup might consist of patients who are using a SB as
their main patch and would like to alternate with a more
skin-friendly patch, keeping in mind that the median device
life of the standard SB is roughly 1.8 times longer because of
its stickier adhesive material.9 These patients may beneﬁt
when they prefer a stable base around the tracheostomy, but
cannot use the SB (all day) due to sensitive/breached skin.
The results show that the device life of the SBO is not
signiﬁcantly increased compared with the OD (both hydrocol-
loid adhesives). However, for those 15 patients who had an
increased device life with the SBO compared with the OD, the
increase is clinically relevant. Thedifference (19.60hoursversus
14.47hours) oftenmade it possible for thosepatients to replace
thepatchonlyonceper24hours.Nevertheless, amajorityof the
patients preferred the normally used patch, because in the
absence of skin irritation, the duration of the seal is the decisive
factor for their ‘patch-choice’. As the mean interval betweenTL
andparticipation in thisstudywas6.5years,most patientshave
extensive experience with several peristomal attachment pos-
sibilities and found their optimal attachment modality. Still,
there are patients (23.3%) who prefer the SBO to their normally
used patch. These results show there are still possibilities for
further innovation, despite the wide range of patches already
available to laryngectomized patients which is not surprising,
given thewidevariations inperistomal anatomy.14 So far, onlya
few clinical studies have been conducted to investigate peristo-
mal patches. Because of the wide variety of rehabilitation
options for laryngectomized patients, however, a good insight
in patients’needs is necessary toﬁnd theoptimal rehabilitation
options. For instance, the study byHilgers et al (2012) describes
that there is no one-size-ﬁts-all solution and emphasizes the
need for a range of device options, which means that this new
patch is a welcome development.9
In thepresent, relatively small study, although therewas no
selection based on the presence or absence of skin irritation,
there still might have been some selection bias. For example,
patientswhowere unable touse the SBO, such aspatientswith
anatomical irregularities in the area of the patch that interfere
with the stable base of the patch,were excluded. Furthermore,
some variables that might inﬂuence device life were not
collected. For example, we did not ask the patients to register
hours of ASV use in their diaries and we did not measure
tracheostomy dimensions and local anatomy, factors that
obviously can inﬂuence the outcomes.8
The cost of these newpatcheswas not a topic of this study.
Although according to the manufacturer the periodical costs
for various patches is quite comparable, to analyze costs in a
meaningful way, a proper cost-effectiveness study would
have been needed. This would require collecting additional
data to those of a standard clinical study. Moreover, since
costs and reimbursement systems vary widely between
countries, even making vague suggestions about cost issues
now would be speculative, at best. But this is certainly an
interesting topic for studies in other countries.
Conclusion
Most patients preferred their normally used patch and SBO
was favored by a subgroup. Therefore, SBO seems to be a
valuable addition to the arsenal of devices already available
and widens the options laryngectomized patients have for
peristomal attachment of medical devices for pulmonary
protection and rehabilitation.
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